The Estimate Gap

Street consensus has OSCR earning ≈$1.00 EPS for 2026. Management just guided $250-450M operating income, which translates to $0.72-$1.30 EPS (midpoint $1.01) after tax.

But here's what matters: The stock at $12.66 (RSI 16.3, down 28% in one month) is pricing something far worse than breakeven. Analyst sentiment is 30% bearish vs 10% bullish, with two Sell ratings and one Strong Sell. The market thinks 2026 looks like 2025.

2025 was ugly: $(396M) operating loss, 87.4% MLR (95.4% in Q4), $(443M) net loss. The ACA marketplace had an industry-wide morbidity spike, and Oscar's healthier member mix meant they owed $(2.6B) into the risk adjustment pool.

Management is guiding a complete reversal for 2026:

  • Revenue: $18.7-19.0B (+60% YoY)
  • MLR: 82.4-83.4% (400-500 bps improvement)
  • Operating income: $250-450M (vs $(396M) loss)
  • Membership: ≈3.4M (record high)

Why The Guidance Has Credibility

This isn't aspirational. The math is already locked:

Revenue side: 3.4M members already enrolled. Premiums already set for 2026. Oscar took 28% rate increases across the book during open enrollment, and membership still surged. The revenue number has visibility.

MLR improvement: The 400-500 bps improvement comes from aggressive repricing for known 2025 morbidity. They're not forecasting utilization will magically drop—they priced for it.

Institutional validation: JPMorgan, Wells Fargo, Barclays, and Morgan Stanley just extended a $475M revolving credit facility (Feb 6, 2026). Covenants require >$3B quarterly premiums (already exceeding) and minimum liquidity. Banks don't lend to a company they think is broken.

This Is Sector-Wide, Not OSCR-Specific

The reviewer flagged "cross-ticker sector convergence," and they're right. Every managed care name is calling 2026 a repricing reset:

  • ELV (Elevance): Exiting unprofitable Medicare Advantage markets, repositioning for "meaningful margin improvement" to at least 2% in 2026 (>100 bps improvement)
  • CNC (Centene): Guiding >$3.00 adj EPS for 2026 vs $2.08 in 2025 (+44%), with HBR improvement of 95 bps in Commercial
  • MOH (Molina): Down 55% over one year, similar repricing dynamics

The ACA marketplace specifically had a 2025 reset. Oscar wasn't uniquely bad—they were exposed to the same industry-wide utilization and risk adjustment dynamics. The difference is Oscar repriced aggressively and grew membership, which suggests competitive product despite higher rates.

The Bear Case

Fair concerns:

  1. Execution risk: This company just lost $(443M). Forward guidance from a miss deserves skepticism. Credibility at 0.7, not 0.95.

  2. Utilization variance: MLR guidance assumes repricing covers elevated morbidity. If 2026 utilization spikes beyond 2025 levels, margins compress. This business is sensitive to utilization trends.

  3. APTC expiration: Enhanced ACA subsidies expire end of 2025 unless extended. Affects 5.5M Marketplace members across the sector (including OSCR's 3.4M). Political risk.

  4. No profitability track record: OSCR has never sustained profitability at scale. Accumulated deficit $(3.3B), equity $981M. This is a "trust the turnaround" story, not a proven operator.

  5. High beta (1.90), high idio vol (80%): In any market selloff or sector rotation, this gets hit hard.

What The Math Says

If guidance delivers:

  • Midpoint operating income: $350M
  • After-tax net income: ≈$260M
  • EPS: ≈$1.00
  • At $12.66: P/E ≈13x on 2026 earnings

For a company growing revenue 60% YoY with 3.4M members and institutional credit facility backing, that's not expensive if the turnaround is real.

The question is: Do you believe 2026 will look like the guidance or like 2025?

Market (RSI 16.3, -28% in one month, bearish analyst sentiment) is pricing "2025 continues." Management is guiding "2026 is the repricing payoff." The estimate gap is the alpha.

Limitations

  • Edge is limited: This is a sector trade (managed care repricing), not a company-specific insight. ELV, CNC, MOH all have the same setup. OSCR is the most beaten-down, but also the most execution-risky (no profitability history).

  • Factor exposure: 1.9 beta, high sensitivity to market. Variance driven by regulatory factors (APTC policy, risk adjustment mechanics), not idiosyncratic company performance.

  • Timing risk: Earnings are public (Feb 10, 2026), call is today. Market is digesting in real time. Alpha window may have closed.

Verdict

Not urgent. Not obvious.

The setup is: deeply oversold stock (RSI 16.3) with street modeling continued losses while management guides $250-450M operating income, corroborated by sector-wide repricing convergence and institutional credit validation.

The risk is: forward guidance from a company that just missed badly, with utilization variance and APTC political risk as material unknowns.

If you have conviction on:

  1. ACA marketplace repricing thesis (sector-wide, not OSCR-specific)
  2. Management execution (unproven)
  3. Utilization stabilization (key variable)

Then $12.66 with RSI 16.3 is an entry. But this is a binary bet on guidance credibility, not a margin-of-safety compounding story.

Position sizing: Low conviction starter (<2%) unless you have unusual insight into ACA marketplace utilization trends or APTC extension probability. Most of the variance is regulatory/sector, not company-specific edge.

Update: Stock trading $12.66 (+3.4% today) on 14.4M volume (2.8x weekly average). Market is processing the guidance in real time.